Bernardo Frison Spiazzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bernardo Frison Spiazzi has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Gerchman
Programa de Pós-Graduação em Ciências Médicas: Endocrinologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
7 shared publications - Verônica Colpani
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil
5 shared publications - Giovana Fagundes Piccoli
Graduate Program in Medical Sciences: Endocrinology Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
4 shared publications - Laura Fink Wayerbacher
Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
3 shared publications - Leonardo de Andrade Mesquita
Graduate Program in Medical Sciences: Endocrinology Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
3 shared publications - Ana Cláudia Duarte
Programa de Pós-Graduação em Ciências Médicas: Endocrinologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
2 shared publications
Latest Publications
- 1 May 2026
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (7) , 1641-1643
Venous Thromboembolism Risk Among Different Statins: A Retrospective Cohort Study
- 1 May 2026
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (7) , 1641-1643
Venous Thromboembolism Risk Among Different Statins: A Retrospective Cohort Study
- Open Access
Ultra-Processed Food Intake as an Effect Modifier in the Association Between Depression and Diabetes in Brazil: A Cross-Sectional Study
Background/Objectives: Recent studies linked a diet rich in ultra-processed foods (UPFs) with depression and diabetes. Although common risk factors, such as aging, are defined for both diseases, how UPFs are associated with the bidirectional relationship between them is not known. This study aimed to investigate whether UPF intake modifies the association between depression and diabetes within the Brazilian adult population. Methods: This cross-sectional analysis utilized data from the 2019 Brazilian National Health Survey, involving over 87,000 adults (aged 18–92 years). Participants provided self-reported data on diabetes and depression diagnoses, dietary habits (assessed by qualitative FFQ), as well as demographic, and socioeconomic variables. Multivariate logistic regression models were used to evaluate the associations, employing two classification methods—UPF1 and UPF2—based on different thresholds of weekly consumption, for high/low UPF intake. Analyses were stratified by age groups to identify variations in associations. Results: There was a significant association between depression and diabetes, especially among participants with high UPF consumption. Models adjusted by demographic characteristics, as well as meat and vegetable consumptions, demonstrated elevated odds ratios (ORs) for diabetes among individuals with depression consuming high levels of UPF, compared to those with a low UPF intake (OR: 1.258; 95% CI: 1.064–1.489 for UPF1 and OR: 1.251; 95% CI: 1.059–1.478 for UPF2). Stratified analysis by age further amplified these findings, with younger individuals showing notably stronger associations (non-old adult group OR: 1.596; 95% CI: 1.127–2.260 for UPF1, and OR: 6.726; 95% CI: 2.625–17.233 for UPF2). Conclusions: These findings suggest that high UPF intake may influence the relationship between depression and diabetes, especially in younger adults. Future longitudinal studies are warranted to establish causality, investigate underlying biological mechanisms, and examine whether improving overall nutrient intake through dietary interventions can reduce the co-occurrence of depression and diabetes.
Open AccessUltra-Processed Food Intake as an Effect Modifier in the Association Between Depression and Diabetes in Brazil: A Cross-Sectional Study
Background/Objectives: Recent studies linked a diet rich in ultra-processed foods (UPFs) with depression and diabetes. Although common risk factors, such as aging, are defined for both diseases, how UPFs are associated with the bidirectional relationship between them is not known. This study aimed to investigate whether UPF intake modifies the association between depression and diabetes within the Brazilian adult population. Methods: This cross-sectional analysis utilized data from the 2019 Brazilian National Health Survey, involving over 87,000 adults (aged 18–92 years). Participants provided self-reported data on diabetes and depression diagnoses, dietary habits (assessed by qualitative FFQ), as well as demographic, and socioeconomic variables. Multivariate logistic regression models were used to evaluate the associations, employing two classification methods—UPF1 and UPF2—based on different thresholds of weekly consumption, for high/low UPF intake. Analyses were stratified by age groups to identify variations in associations. Results: There was a significant association between depression and diabetes, especially among participants with high UPF consumption. Models adjusted by demographic characteristics, as well as meat and vegetable consumptions, demonstrated elevated odds ratios (ORs) for diabetes among individuals with depression consuming high levels of UPF, compared to those with a low UPF intake (OR: 1.258; 95% CI: 1.064–1.489 for UPF1 and OR: 1.251; 95% CI: 1.059–1.478 for UPF2). Stratified analysis by age further amplified these findings, with younger individuals showing notably stronger associations (non-old adult group OR: 1.596; 95% CI: 1.127–2.260 for UPF1, and OR: 6.726; 95% CI: 2.625–17.233 for UPF2). Conclusions: These findings suggest that high UPF intake may influence the relationship between depression and diabetes, especially in younger adults. Future longitudinal studies are warranted to establish causality, investigate underlying biological mechanisms, and examine whether improving overall nutrient intake through dietary interventions can reduce the co-occurrence of depression and diabetes.
- 18 November 2024
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 218, 111933
SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis
- 18 November 2024
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 218, 111933
SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis
- 16 September 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (1) , 39-49
Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes across the Spectrum of Kidney Disease
Key Points: The effect of sodium-glucose cotransporter 2 inhibitors in preventing kidney outcomes in populations at lower risk of kidney disease remains uncertain. Pooled data from randomized controlled trials show that sodium-glucose cotransporter 2 inhibitors prevent kidney outcomes across the spectrum of kidney disease risk. Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with CKD at high risk of adverse outcomes. The effect of these agents in preventing clinically meaningful kidney outcomes in populations at lower risk remains uncertain. We aim to evaluate the effect of SGLT2 inhibitors on kidney outcomes across the Kidney Disease Improving Global Outcomes (KDIGO) classification and urinary albumin-creatinine ratio (UACR) levels. Methods: We have searched medical literature analysis and retrieval system online (PubMed), excerpta medica database, and Cochrane Central Register of Controlled Trials from inception up to August 8, 2023. In pairs, researchers selected large (≥500 participants per arm) randomized placebo-controlled trials of SGLT2 inhibitors, with a minimum duration of 1 year. Researchers independently extracted study-level data and assessed within-study risk of bias with the risk of bias 2.0 tool and quality of evidence with grading of recommendations, assessment, development and evaluation. Results: We included ten trials, encompassing 78,184 participants and a median follow-up of 2.7 years. Risk of bias was overall low. We performed meta-analyses summarizing individual study hazard ratios (HRs) and 95% confidence intervals (CIs) using a random-effects model. SGLT2 inhibitors reduced the composite kidney outcome across all KDIGO (HR [95% CI]: low 0.48 [0.32 to 0.71], moderate 0.60 [0.39 to 0.93], high 0.59 [0.47 to 0.74], very high 0.59 [0.49 to 0.72]) and UACR (HR [95% CI]: 300 mg/g 0.61 [0.52 to 0.73]) groups, without evidence of heterogeneity between groups. A small proportion of participants without diabetes in low-risk groups were referred, and there was lack of standardization of composite outcomes. Conclusions: SGLT2 inhibitors consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels. Clinical Trial registry name and registration number: CRD42023492877.
- 16 September 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (1) , 39-49
Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes across the Spectrum of Kidney Disease
Key Points: The effect of sodium-glucose cotransporter 2 inhibitors in preventing kidney outcomes in populations at lower risk of kidney disease remains uncertain. Pooled data from randomized controlled trials show that sodium-glucose cotransporter 2 inhibitors prevent kidney outcomes across the spectrum of kidney disease risk. Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with CKD at high risk of adverse outcomes. The effect of these agents in preventing clinically meaningful kidney outcomes in populations at lower risk remains uncertain. We aim to evaluate the effect of SGLT2 inhibitors on kidney outcomes across the Kidney Disease Improving Global Outcomes (KDIGO) classification and urinary albumin-creatinine ratio (UACR) levels. Methods: We have searched medical literature analysis and retrieval system online (PubMed), excerpta medica database, and Cochrane Central Register of Controlled Trials from inception up to August 8, 2023. In pairs, researchers selected large (≥500 participants per arm) randomized placebo-controlled trials of SGLT2 inhibitors, with a minimum duration of 1 year. Researchers independently extracted study-level data and assessed within-study risk of bias with the risk of bias 2.0 tool and quality of evidence with grading of recommendations, assessment, development and evaluation. Results: We included ten trials, encompassing 78,184 participants and a median follow-up of 2.7 years. Risk of bias was overall low. We performed meta-analyses summarizing individual study hazard ratios (HRs) and 95% confidence intervals (CIs) using a random-effects model. SGLT2 inhibitors reduced the composite kidney outcome across all KDIGO (HR [95% CI]: low 0.48 [0.32 to 0.71], moderate 0.60 [0.39 to 0.93], high 0.59 [0.47 to 0.74], very high 0.59 [0.49 to 0.72]) and UACR (HR [95% CI]: 300 mg/g 0.61 [0.52 to 0.73]) groups, without evidence of heterogeneity between groups. A small proportion of participants without diabetes in low-risk groups were referred, and there was lack of standardization of composite outcomes. Conclusions: SGLT2 inhibitors consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels. Clinical Trial registry name and registration number: CRD42023492877.
- 23 February 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (5) , 1929-1940
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis
Aim: To evaluate the effect of metformin on cancer incidence in subjects with overweight/obesity and/or prediabetes/diabetes. Materials and Methods: We searched MEDLINE, Embase and CENTRAL for randomized controlled trials (RCTs) in adults with overweight/obesity and/or prediabetes/diabetes that compared metformin to other interventions for ≥24 weeks. Independent reviewers selected and extracted data including population and intervention characteristics and new diagnoses of cancer. We used the RoB 2.0 risk‐of‐bias tool and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework to assess risk of bias and certainty of evidence. Results: From 14 895 records after removal of duplicates, 27 trials were included, providing a total of 10 717 subjects in the metformin group and 10 003 in the control group, with 170 and 208 new cases of cancer, respectively. Using a random‐effects model, the relative risk was 1.07 (95% confidence interval 0.87–1.31), with similar results in subgroup analyses by study duration or effect of control intervention on weight. Risk of bias in most studies was low, and no evidence of publication bias was found. Trial sequential analysis provided evidence that the cumulative sample size was large enough to exclude a significant effect of metformin on cancer incidence. Conclusions: Metformin did not reduce cancer incidence in RCTs involving subjects with overweight/obesity and/or prediabetes/diabetes.
- 23 February 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (5) , 1929-1940
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis
Aim: To evaluate the effect of metformin on cancer incidence in subjects with overweight/obesity and/or prediabetes/diabetes. Materials and Methods: We searched MEDLINE, Embase and CENTRAL for randomized controlled trials (RCTs) in adults with overweight/obesity and/or prediabetes/diabetes that compared metformin to other interventions for ≥24 weeks. Independent reviewers selected and extracted data including population and intervention characteristics and new diagnoses of cancer. We used the RoB 2.0 risk‐of‐bias tool and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework to assess risk of bias and certainty of evidence. Results: From 14 895 records after removal of duplicates, 27 trials were included, providing a total of 10 717 subjects in the metformin group and 10 003 in the control group, with 170 and 208 new cases of cancer, respectively. Using a random‐effects model, the relative risk was 1.07 (95% confidence interval 0.87–1.31), with similar results in subgroup analyses by study duration or effect of control intervention on weight. Risk of bias in most studies was low, and no evidence of publication bias was found. Trial sequential analysis provided evidence that the cumulative sample size was large enough to exclude a significant effect of metformin on cancer incidence. Conclusions: Metformin did not reduce cancer incidence in RCTs involving subjects with overweight/obesity and/or prediabetes/diabetes.
- Open Access
- 21 June 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (6) , e000641
Coconut oil: an overview of cardiometabolic effects and the public health burden of misinformation
Recent data from meta-analyses of randomized clinical trials (RCTs) suggest that dietary intake of coconut oil, rich in saturated fatty acids, does not result in cardiometabolic benefits, nor in improvements in anthropometric, lipid, glycemic, and subclinical inflammation parameters. Nevertheless, its consumption has surged in recent years all over the world, a phenomenon which can possibly be explained by an increasing belief among health professionals that this oil is as healthy as, or perhaps even healthier than, other oils, in [...] ABSTRACT Recent data from meta-analyses of randomized clinical trials (RCTs) suggest that dietary intake of coconut oil, rich in saturated fatty acids, does not result in cardiometabolic benefits, nor in improvements in anthropometric, lipid, glycemic, and subclinical inflammation parameters. Nevertheless, its consumption has surged in recent years all over the world, a phenomenon which can possibly be explained by an increasing belief among health professionals that this oil is as healthy as, or perhaps even healthier than, other oils, in
- 21 June 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (6) , e000641
Open AccessCoconut oil: an overview of cardiometabolic effects and the public health burden of misinformation
Recent data from meta-analyses of randomized clinical trials (RCTs) suggest that dietary intake of coconut oil, rich in saturated fatty acids, does not result in cardiometabolic benefits, nor in improvements in anthropometric, lipid, glycemic, and subclinical inflammation parameters. Nevertheless, its consumption has surged in recent years all over the world, a phenomenon which can possibly be explained by an increasing belief among health professionals that this oil is as healthy as, or perhaps even healthier than, other oils, in [...] ABSTRACT Recent data from meta-analyses of randomized clinical trials (RCTs) suggest that dietary intake of coconut oil, rich in saturated fatty acids, does not result in cardiometabolic benefits, nor in improvements in anthropometric, lipid, glycemic, and subclinical inflammation parameters. Nevertheless, its consumption has surged in recent years all over the world, a phenomenon which can possibly be explained by an increasing belief among health professionals that this oil is as healthy as, or perhaps even healthier than, other oils, in
- 10 February 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 32 (6) , 1375-1384
Misinformation in nutrition through the case of coconut oil: An online before-and-after study
- 10 February 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 32 (6) , 1375-1384
Misinformation in nutrition through the case of coconut oil: An online before-and-after study
- 1 December 2020
- Published by Wiley in Obesity Reviews
- Vol. 22 (3)
Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
Summary: The US Food and Drug Administration (FDA) reported in February 2020 an increased risk of cancer with lorcaserin in the follow‐up of the CAMELLIA‐TIMI 61 trial. This systematic review and meta‐analysis addresses whether lorcaserin is associated with higher incidence of cancer compared with other interventions or no treatment. We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for randomized controlled trials that compared lorcaserin with other interventions or no treatment in adults. We performed descriptive synthesis of all included studies and conducted meta‐analysis of trials that reported new cases of cancer. From 11 trials, comprising 21,299 individuals, four studies were included in the meta‐analysis and reported 476 cases of cancer in 10,342 subjects in the lorcaserin group and 438 among 9429 individuals randomized to placebo (relative risk [RR]: 1.08; 95% confidence interval [95% CI]: 0.96–1.23). The result was heavily influenced by the CAMELLIA‐TIMI 61 trial. In this study, the lorcaserin group had a higher risk of lung and pancreatic but not colon cancer. Overall risk of bias was low, and quality of evidence was moderate. The current evidence does not confirm the increased risk of cancer with lorcaserin but suggests a trend in this direction, with a greater incidence of some subtypes such as lung and pancreas.
- 1 December 2020
- Published by Wiley in Obesity Reviews
- Vol. 22 (3)
Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
Summary: The US Food and Drug Administration (FDA) reported in February 2020 an increased risk of cancer with lorcaserin in the follow‐up of the CAMELLIA‐TIMI 61 trial. This systematic review and meta‐analysis addresses whether lorcaserin is associated with higher incidence of cancer compared with other interventions or no treatment. We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for randomized controlled trials that compared lorcaserin with other interventions or no treatment in adults. We performed descriptive synthesis of all included studies and conducted meta‐analysis of trials that reported new cases of cancer. From 11 trials, comprising 21,299 individuals, four studies were included in the meta‐analysis and reported 476 cases of cancer in 10,342 subjects in the lorcaserin group and 438 among 9429 individuals randomized to placebo (relative risk [RR]: 1.08; 95% confidence interval [95% CI]: 0.96–1.23). The result was heavily influenced by the CAMELLIA‐TIMI 61 trial. In this study, the lorcaserin group had a higher risk of lung and pancreatic but not colon cancer. Overall risk of bias was low, and quality of evidence was moderate. The current evidence does not confirm the increased risk of cancer with lorcaserin but suggests a trend in this direction, with a greater incidence of some subtypes such as lung and pancreas.
- 28 November 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (3) , 912-921
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Context: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher absolute number of breast cancer events. Objective: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. Data Sources: We searched MEDLINE, Embase, Web of Science, and CENTRAL from July 31, 2019 to February 8, 2020. Study Selection: Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks. Data Extraction: Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE). Data Synthesis: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48 267 subjects treated with GLP-1RAs, 130 developed breast cancer compared with 107 of 40 755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76–1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48–2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. Conclusions: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.
- 28 November 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (3) , 912-921
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Context: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher absolute number of breast cancer events. Objective: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. Data Sources: We searched MEDLINE, Embase, Web of Science, and CENTRAL from July 31, 2019 to February 8, 2020. Study Selection: Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks. Data Extraction: Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE). Data Synthesis: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48 267 subjects treated with GLP-1RAs, 130 developed breast cancer compared with 107 of 40 755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76–1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48–2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. Conclusions: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.